Photo of Giuseppe Lombardi from www.pugliaeccellente.info
Sep 24, 2024, 23:18
Giuseppe Lombardi: Pleased to announce the academic MIRAGE trial for patients with recurrent grade 2-3 meningioma
Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a post on LinkedIn:
”I am pleased to announce the academic MIRAGE trial for patients with recurrent grade 2-3 meningioma. This is the first randomized trial to evaluate a tyrosine kinase inhibitor in meningioma.”
Source: Giuseppe Lombardi/LinkedIn
Giuseppe Lombardi is the Head of the Neuro-Oncology Unit at Veneto Oncology Institute IOV – IRCCS and Oncologist MD at Veneto Oncology Institute of Padua. Previously, he has been part of the neuro – oncology faculty at the Memorial Sloan Kettering Cancer Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14